CARMOT THERAPEUTICS
Carmot Therapeutics provides drugs to treat inflammatory, metabolic, and neurological diseases. They employ their patented technology, Chemotype Evolution, to address the fundamental causes of disease and speed the discovery of disease-modifying therapies. Carmot Therapeutics is headquartered in San Francisco, California and was founded in 2008.
CARMOT THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2008-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.carmot-therapeutics.us
Total Employee:
1+
Status:
Active
Contact:
5105279251
Email Addresses:
[email protected]
Total Funding:
234.85 M USD
Technology used in webpage:
SPF Google Apps For Business Unified Layer BlueHost BlueHost DNS BlueHost Mail
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
Willett Advisors LLC
Willett Advisors LLC investment in Series D - Carmot Therapeutics
Deep Track Capital
Deep Track Capital investment in Series D - Carmot Therapeutics
The Column Group
The Column Group investment in Series D - Carmot Therapeutics
RA Capital Management
RA Capital Management investment in Series D - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series D - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series C - Carmot Therapeutics
The Column Group
The Column Group investment in Series C - Carmot Therapeutics
Amgen Ventures
Amgen Ventures investment in Series C - Carmot Therapeutics
The Column Group
The Column Group investment in Series B - Carmot Therapeutics
Horizons Ventures
Horizons Ventures investment in Series B - Carmot Therapeutics
Official Site Inspections
http://www.carmot-therapeutics.us Semrush global rank: 5.15 M Semrush visits lastest month: 1.57 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Carmot Therapeutics"
Carmot Therapeutics Enters into Definitive Merger Agreement …
BERKELEY, Calif., December 3, 2023 (GLOBE NEWSWIRE) — Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing …See details»
About Us | Carmot Therapeutics | Drug Discovery and Development
This platform enabled us to design a pipeline of incretin therapeutics intended to exhibit the appropriate balance of bias and desirable therapeutic attributes. Carmot’s founders had a …See details»
Carmot Therapeutics, Inc. | LinkedIn
Carmot Therapeutics, Inc. | 8,270 followers on LinkedIn. Carmot has been acquired by Roche in early 2024, making the company a member of the Roche Group. Carmot Therapeutics is a clinical-stage ...See details»
Roche enters into a definitive merger agreement to …
Dec 4, 2023 Carmot Therapeutics (Carmot) is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes.See details»
Carmot Therapeutics Enters into Definitive Merger Agreement …
Dec 4, 2023 Carmot Therapeutics – Roche to acquire Carmot for an upfront payment of $2.7 billion and the potential for $400 million in milestone payments – – Carmot will join the Roche …See details»
Roche joins race for obesity drugs with $2.7 billion …
Dec 4, 2023 Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs ...See details»
Carmot Therapeutics Announces Completion of Acquisition by …
Jan 29, 2024 Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including …See details»
Roche enters into a definitive merger agreement to acquire …
Dec 4, 2023 Carmot Therapeutics’ s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in …See details»
Carmot Therapeutics - Crunchbase Company Profile & Funding
Carmot Therapeutics may be growing as evidenced by the acquisition by Roche for up to $3.1 billion, which is a significant financial transaction indicating a valuation increase. ... 9,915 …See details»
Carmot Therapeutics Enters Definitive Merger Agreement With …
San Francisco – December 3, 2023 – Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living …See details»
Our Approach | Carmot Therapeutics | Drug Discovery and …
Carmot was acquired by Roche in early 2024. Modulating core energy homeostatic pathways is critical to addressing this disease burden. Carmot’s clinical pipeline targets two main incretins, …See details»
Carmot Therapeutics Announces Significant Leadership Team …
Sep 21, 2022 Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype EvolutionSee details»
Carmot Therapeutics Inc. (CRMO) Company Profile & Overview
Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. …See details»
Roche to buy Carmot for up to $3.1bn as race for ... - Financial Times
Dec 4, 2023 Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing …See details»
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to …
BERKELEY, Calif., January 5, 2023 (GLOBE NEWSWIRE) — Carmot Therapeutics, Inc. (Carmot), a clinical-stage biotechnology company developing disease-modifying therapies for …See details»
Carmot Therapeutics closes $160 million Series D financing to …
Carmot Therapeutics, Inc. 740 Heinz Avenue Berkeley, CA 94710 www.carmot.us Phase 2 development and has the potential to be best in a new class of treatments for obesity and its …See details»
Carmot Therapeutics Raises $150 Million in Series E Equity …
May 25, 2023 Carmot Therapeutics – Proceeds to support development of Carmot's broad clinical-stage metabolic pipeline including two Phase 2 trials of CT-388, a once weekly, dual …See details»
News | Carmot Therapeutics | Drug Discovery and Development
Jan 29, 2024 Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for …See details»
Drug Discovery and Development - Carmot Therapeutics
Drug Discovery and Development. CT-996/RG6652 GLP-1 Receptor Agonist . Carmot is currently conducting a double-blind, placebo-controlled Phase 1 clinical trial of CT-996 in participants …See details»